drugset
drugset / Trial / NCT06898970

Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

NCT06898970 ↗

Phase 2 Active not recruiting 18 enrolled Varun Monga, MBBS Replimune, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in participants with advanced angiosarcoma who have progressed after prior immunotherapy.

Timeline

Start
2026-01-09
Primary completion
2029-10-31
Completion
2029-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Subject Vusolimogene Oderparepvec Unknown — Other

Indications

angiosarcoma